A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

9123AALL1732-NCT03959085OpenA Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLyAALL1732NCT03959085NationalChildrenTreatmentIIINationalLeukemia, otherPudela, CaileighGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterPediatricsOncology GroupLombardi Comprehensive Cancer Center (LCCC); NCA MU NCORP2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>